Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
Date:3/20/2012

lacebo-controlled efficacy and safety trial in adults following open abdominal surgery.  Approximately 150 adults, randomized 2:1 to active or placebo treatment groups, will be treated for post-operative pain for 48 - 72 hours after randomization.  
  • A second Phase 3 study is planned as an open-label, active-comparator study comparing ARX-01 to the current standard of care, intravenous patient-controlled analgesia, with morphine. The primary endpoint for this study will assess a measure of efficacy, Global Patient Satisfaction over the 48-hour study period, and will compare ratings of "Good" and "Excellent" for Global Patient Satisfaction between the two groups in a non-inferiority comparison.
  • The third and final planned Phase 3 clinical study is a randomized, double-blind, placebo-controlled efficacy and safety study comparing ARX-01 to placebo for post-operative pain control following major joint replacement surgery.

  • Financial OutlookAcelRx anticipates that research and development expenses will increase significantly over the next several quarters as AcelRx seeks to complete Phase 3 clinical development of ARX-01. The development of ARX-04 beyond Phase 2 and initial preparations for Phase 3 are dependent on the identification of sources of additional funding from the USAMRMC or the identification of a partner to support these efforts.  Additionally, AcelRx anticipates modest increases in general and administrative expenses due to costs associated with operating as a public company and expansion of its corporate infrastructure to support ongoing development of its product candidates.

    AcelRx believes its current cash, cash equivalents and investments are sufficient to fund operations into the first quarter of 2013.

    About AcelRx Pharmaceuticals, Inc. Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) i
    '/>"/>

    SOURCE AcelRx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
    2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
    3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
    4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
    5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
    6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
    7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
    8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
    9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
    10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
    11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
    (Date:7/31/2015)... 2015 More than 1,500 substance abuse prevention ... in Indianapolis Aug. 2-6 for ... Training Institute . The week-long training, held at the ... of our nation,s biggest public health challenges – youth ... is a one-of-a-kind intensive training opportunity, offering more than ...
    (Date:7/31/2015)... 31, 2015 RnRMarketResearch.com adds ... research report that provides an overview of syringes ... sourced from in-house databases, secondary and primary research. ... market products pipeline spread across 124 pages, talking ... tables and 5 figures is now available at ...
    Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5
    ... display at Rockefeller Plaza this month will emphasize ... almost 250,000 people per day with this important ... Industry Foundation,s National Colorectal Cancer Research Alliance (EIF,s ... Prevention,s (CDC,s) Screen for Life: National Colorectal ...
    ... -- CK Life Sciences Int,l., (Holdings) Inc. ("CK Life Sciences" ... and Drug Administration) has granted clearance for its subsidiary Polynoma ... proceed with Phase III clinical testing of its melanoma vaccine. ... sian Companies Cleared by FDA for Phase III Clinical Trial ...
    Cached Medicine Technology:EHE International Joins Forces With Entertainment Industry Foundation's National Colorectal Cancer Research Alliance and the CDC to Encourage Screening 2CK Life Sciences Announces U.S. FDA's Clearance to Commence Phase III Clinical Testing of Melanoma Vaccine 2CK Life Sciences Announces U.S. FDA's Clearance to Commence Phase III Clinical Testing of Melanoma Vaccine 3
    (Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma ... store can be accessed by visiting http://www.curemeso.org/store . , “Our new store ... best part: whenever a product is purchased, the Meso Foundation receives a $5.00 ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Sculpted Contours ... the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the ... January 2014 for treating the outer thighs. The original applicator required a 2 ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... an important workshop at its new True North Conference Center. The medical community, ... that the Jacksonville community may be more aligned in the effort to better ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Coco Libre ... athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, July ... water that can claim “no added sugar” on the market, is a natural choice ...
    Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
    ... of a complex signaling network in the developing brain ... congenital brain malformation, Yale School of Medicine researchers report ... variety of neurological disorders such as epilepsy, mental retardation, ... and genetic causes, but is most commonly due to ...
    ... is probing the link between breast density and its implication ... novel study on 1,112 women has brought to the fore, ... with dense breasts. The study revealed that, those with dense ... breast cancer, compared to women with fatty tissue in the ...
    ... of Vertebral Subluxation Research (JVSR), suggests that chiropractic ... from learning disabilities and dyslexia. ,The ... DC, president of the Swiss Chiropractic Pediatric Association, ... from learning and behavioral disorders. ,"This ...
    ... painkillers, especially the likes of Ibuprofen and Aspirin, which come ... out or exercise. A new study has suggested that the ... work out, may ease muscle pain by 50%. ... of kinesiology at the University of Georgia, Athens, 'A lot ...
    ... researchers who studied winners and nominees of the Nobel ... status and health in monkeys, but it has been ... status often brings more wealth, which improves living standards ... Scientist., ,Andrew Oswald and Matthew Rablen, economists at ...
    ... for chemotherapy which would have none of the unbearable side ... in the Canadian journal Cancer Cell. // ,The scientists ... DCA or the dichloroacetate which like a usual tablet can ... consumed. The greater advantage of DCA is its cost effectiveness ...
    Cached Medicine News:Health News:Missing Molecule Has Important Role in a Developmental Brain Abnormality 2Health News:Chiropractic Care Helps Children With Learning Disorders and Dyslexia 2Health News:Chiropractic Care Helps Children With Learning Disorders and Dyslexia 3Health News:Work-outs, Not So Much of a ‘pain’ With Caffei 2
    A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
    Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
    Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
    Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
    Medicine Products: